Amyotrophic lateral sclerosis
Conditions
Interventions
Sponsors
Medical corporation foundation Kouseikai Takeda Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: For the subject of this study, the Takeda Hospital neurologist and this medical treatment medical attendant performs confirmation, the medical examination of the anamnesis. Among patients meeting amyotrophy-related lateral sclerosis medical treatment guidelines diagnostic criteria, the purpose of this study is understood and intends for a patient of the amyotrophic lateral sclerosis to have a poor intractable disease in the effectiveness by the existing cure that obtained consent in a document. Age, the sex do not matter. 1 The target disease patient who was admitted to the Takeda Hospital in an operation and treatment, an inspection purpose 2 The target disease patient who visits a hospital for treatment in the outpatient department of the Takeda Hospital 3 The patient who acquired an agreement of this study entry by the free will of the person in a document
Exclusion criteria
Exclusion criteria: The patient corresponding to the following standards excludes it from a patient targeted for the final examination. 1 The person that quantity of fat necessary for this study is not provided 2 The patient whom I am dialyzing 3 Pregnant patient 4 This study medical attendant is the patient who ethical, it is scientific, and made a decision from the viewpoint of safety if the participation in this study is inappropriate of the subject 5 The patient who needs Agent approval I confirm an anamnesis to advocate next and, from having experience or not that underwent a blood transfusion or transplant, do a competent thing judging. But I decide to reconfirm when I become able to confirm it about the anamnesis which I was not able to confirm at the time of a competent judgment later. 1 Infection with bacteria such as Treponema pallidum, a gonococcus, the tubercle bacillus 2 Sepsis and the doubt 3 Malignant tumor 4 Serious metabolism internal secretion disease 5 Serious blood disorder 6 Liver disease 7 Communicable spongy brain fever and the doubt 8 Family career to be concerned with a specific hereditary disease and the disease concerned 9 Pulmonary embolism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| I perform the evaluation by an examination for physical views and living body, a laboratory determination. I do not compare the administrated group, the non-administrated group like a clinical trial, and this study medical attendant and neurology medical attendant evaluate a symptom change at a symptom improvement degree in equivalence people over time in comparison with in front of stem cell dosage. I am based on before dosage and evaluate the change of various kinds of symptoms (including dysphagia, an articulation disorder, muscle weakness). | — |
Countries
Japan
Contacts
Public ContactTadayuki Nakayama
Takeda Hospital group headquarters Director of medical management
Outcome results
None listed